Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APRE Aprea Therapeutics	$1.60 +1.9%	$1.74	$1.41 ▼ $5.01	$9.15M	1.29	52,714 shs	12,592 shs
AWH Aspira Women's Health	$0.08 -12.5%	$0.08	$0.08 ▼ $1.56	$2.44M	2.01	1.62 million shs	4.31 million shs
BFRI Biofrontera	$0.89 +1.5%	$0.85	$0.54 ▼ $2.22	$8.92M	0.5	71,259 shs	11,498 shs
KPRX Kiora Pharmaceuticals	$2.62 -1.1%	$2.85	$2.25 ▼ $4.18	$9.10M	-0.64	86,780 shs	29,824 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APRE Aprea Therapeutics	-1.26%	-8.19%	-9.25%	-5.42%	-57.80%
AWH Aspira Women's Health	0.00%	0.00%	0.00%	0.00%	-91.96%
BFRI Biofrontera	-5.37%	-7.36%	+1.27%	+31.79%	-30.70%
KPRX Kiora Pharmaceuticals	-0.75%	+6.43%	-14.24%	-13.68%	-35.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APRE Aprea Therapeutics	3.5566 of 5 stars	3.5	5.0	0.0	0.0	3.2	0.8	1.3
AWH Aspira Women's Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BFRI Biofrontera	2.8249 of 5 stars	3.5	5.0	0.0	0.0	2.3	0.0	0.6
KPRX Kiora Pharmaceuticals	3.1283 of 5 stars	3.3	5.0	0.0	0.0	2.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APRE Aprea Therapeutics	3.00	Buy	$15.50	868.75% Upside
AWH Aspira Women's Health	0.00	N/A	N/A	N/A
BFRI Biofrontera	3.00	Buy	$2.75	207.95% Upside
KPRX Kiora Pharmaceuticals	2.50	Moderate Buy	$10.00	281.68% Upside

Current Analyst Ratings Breakdown

Latest AWH, APRE, BFRI, and KPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/13/2025	KPRX Kiora Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/26/2025	APRE Aprea Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APRE Aprea Therapeutics	$1.50M	6.22	N/A	N/A	$2.30 per share	0.70
AWH Aspira Women's Health	$9.18M	0.27	N/A	N/A	($0.23) per share	-0.36
BFRI Biofrontera	$37.32M	0.24	N/A	N/A	($0.46) per share	-1.94
KPRX Kiora Pharmaceuticals	$16.02M	0.56	$1.22 per share	2.15	$6.44 per share	0.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APRE Aprea Therapeutics	-$12.96M	-$2.32	N/A	N/A	N/A	-1,645.01%	-78.90%	-62.67%	11/6/2025 (Estimated)
AWH Aspira Women's Health	-$16.69M	-$0.98	N/A	∞	N/A	-165.07%	N/A	-267.23%	N/A
BFRI Biofrontera	-$17.76M	-$2.26	N/A	N/A	N/A	-42.34%	-1,104.09%	-82.28%	N/A
KPRX Kiora Pharmaceuticals	$3.60M	-$2.91	N/A	N/A	N/A	N/A	-47.17%	-34.00%	N/A

Latest AWH, APRE, BFRI, and KPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	BFRI Biofrontera	-$0.45	-$0.57	-$0.12	-$0.57	$8.30 million	$9.03 million
8/12/2025	Q2 2025	APRE Aprea Therapeutics	-$0.77	-$0.53	+$0.24	-$0.53	N/A	$0.12 million
8/8/2025	Q2 2025	KPRX Kiora Pharmaceuticals	-$0.58	-$0.54	+$0.04	-$0.54	$0.75 million	$0.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
AWH Aspira Women's Health	$1.04	1,268.29%	N/A	N/A	N/A
BFRI Biofrontera	N/A	N/A	N/A	N/A	N/A
KPRX Kiora Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APRE Aprea Therapeutics	N/A	5.34	5.34
AWH Aspira Women's Health	N/A	0.75	0.70
BFRI Biofrontera	8.99	0.96	0.75
KPRX Kiora Pharmaceuticals	N/A	7.76	7.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APRE Aprea Therapeutics	34.19%
AWH Aspira Women's Health	12.19%
BFRI Biofrontera	10.08%
KPRX Kiora Pharmaceuticals	76.97%

Insider Ownership

Company	Insider Ownership
APRE Aprea Therapeutics	13.63%
AWH Aspira Women's Health	4.30%
BFRI Biofrontera	4.80%
KPRX Kiora Pharmaceuticals	0.05%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APRE Aprea Therapeutics	7	5.83 million	5.03 million	No Data
AWH Aspira Women's Health	110	29.76 million	16.92 million	No Data
BFRI Biofrontera	70	10.14 million	9.65 million	No Data
KPRX Kiora Pharmaceuticals	10	3.43 million	3.43 million	Not Optionable

AWH, APRE, BFRI, and KPRX Headlines

Recent News About These Companies

Kiora Pharmaceuticals Highlights at Ophthalmology Conference

August 13, 2025 | msn.com

Kiora (KPRX) Q2 Revenue Falls 100%

August 8, 2025 | theglobeandmail.com

Kiora Pharmaceuticals Advances Retinal Disease Pipeline

August 8, 2025 | tipranks.com

Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

August 8, 2025 | finanznachrichten.de

Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

August 8, 2025 | finance.yahoo.com

Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases

August 8, 2025 | newsfilecorp.comN

Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease

July 22, 2025 | newsfilecorp.comN

Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know

July 16, 2025 | zacks.com

kiora pharmaceuticals reports results of annual shareholder meeting

June 6, 2025 | investing.com

Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia

June 3, 2025 | finanznachrichten.de

Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia

June 3, 2025 | newsfilecorp.comN

Kiora Pharmaceuticals Reports Q1 2025 Financial Results

May 30, 2025 | tipranks.com

Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027

May 9, 2025 | newsfilecorp.comN

Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy

May 5, 2025 | finance.yahoo.com

Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference

April 4, 2025 | newsfilecorp.comN

Kiora Pharmaceuticals Advances Retinal Disease Pipeline

March 25, 2025 | tipranks.com

Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027

March 25, 2025 | newsfilecorp.comN

Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting

March 12, 2025 | newsfilecorp.comN

Kiora Pharmaceuticals secures new patent for KIO-104

February 13, 2025 | msn.com

Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104

February 13, 2025 | newsfilecorp.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

AWH, APRE, BFRI, and KPRX Company Descriptions

Aprea Therapeutics NASDAQ:APRE

$1.60 +0.03 (+1.91%)

Closing price 03:59 PM Eastern

Extended Trading

$1.64 +0.03 (+2.19%)

As of 07:23 PM Eastern

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Aspira Women's Health NASDAQ:AWH

Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.

Biofrontera NASDAQ:BFRI

$0.89 +0.01 (+1.47%)

Closing price 03:58 PM Eastern

Extended Trading

$0.89 0.00 (0.00%)

As of 06:16 PM Eastern

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Kiora Pharmaceuticals NASDAQ:KPRX

$2.62 -0.03 (-1.13%)

Closing price 04:00 PM Eastern

Extended Trading

$2.57 -0.05 (-2.06%)

As of 07:22 PM Eastern

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time